Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
stapuldencel + docetaxel + prednisone
- Development stage
- Discontinued
- Lead developer
- SOTIO Biotech AG
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Cell Therapies, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination consists of **stapuldencel** (an autologous dendritic cell vaccine, also known as DCVAC/PCa or stapuldencel-T), **docetaxel** (a taxane-class chemotherapeutic agent), and **prednisone** (a synthetic corticosteroid). Stapuldencel is an active cellular immunotherapy using autologous dendritic cells to stimulate the immune system against prostate cancer. Docetaxel inhibits cell division by stabilizing microtubules, leading to apoptosis in rapidly dividing cells. Prednisone is used to help manage inflammation and reduce some of the side effects of chemotherapy while potentially enhancing the effectiveness of docetaxel. This combination has been investigated primarily for metastatic castration-resistant prostate cancer, with stapuldencel providing immunostimulatory effects alongside cytotoxic chemotherapy and supportive corticosteroid therapy[1][4][6][7].
- Other names
- DCVAC/PCaDCVAC-PCadendritic cell vaccine/prostate cancerstapuldencel-T
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on stapuldencel + docetaxel + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on stapuldencel + docetaxel + prednisone.